logo
Bankrupt council hits disabled residents with ‘blue badge tax'

Bankrupt council hits disabled residents with ‘blue badge tax'

Yahoo19-03-2025

A bankrupt council has hit disabled drivers with a £25 parking charge as it struggles to plug a £2.1bn hole in its finances.
Woking Borough Council will ask Blue Badge holders to pay the 'administration fee' for a permit allowing them to park in council car parks for free.
The authority said the fee was 'reasonable' given the 'extraordinary' amount of time spent processing applications to the scheme.
Blue badges cost up to £10 in England and entitle holders to free on-street parking. They are renewed every three years.
The extra permit would allow drivers to also park for free in council-run car parks in Woking town centre and would expire in-line with residents' blue badges.
Woking Borough Council was forced to declare itself effectively bankrupt in June 2023 after a slew of risky property investments and regeneration deals landed the authority with a £2.1bn deficit.
A government commissioner report published this month found that even if the council sold everything it owned, it would still be more than £1.5bn in deficit. It added that servicing the debt was costing £1.3m a week in interest alone.
The council said that much of the £30,000 cost of the additional permit scheme was because its car parks use automatic number plate recognition (ANPR) technology – which requires a chip to be installed in every blue badge – rather than being pay-and-display.
Disability campaigners reacted furiously to the proposal. Cliff Bush OBE, who chairs Woking Access Group, said he was 'absolutely beyond rage' at the plans, which would reduce accessibility for disabled residents and amounted to a 'disability tax'.
He added: 'The council doesn't own the car parks, residents do, and I pay my council tax.'
Nikki Roberts, chief executive of the Surrey Coalition of Disabled People, said the 'upsetting and unfair' fee risked increasing social isolation among disabled people.
She added: 'The cost of living crisis is disproportionately affecting disabled people, as day-to-day life is more expensive and they tend to live in low-income households. This will only make the problem worse.'
Woking is one of many cash-strapped councils across the country looking at creative ways to raise funds. The authority has already slashed 'discretionary' spending on services – including buses, public toilets and community care projects.
Similarly, Liverpool City Council is increasing on-street parking costs by 60pc and off-street parking by nearly 50pc. For the first time, shoppers in Harpenden will have to pay £2.50 an hour to park on the high street as St Albans City and District Council attempts to boost its coffers.
It comes as nine in 10 town halls across the country are raising council tax by the maximum 5pc from April – while services are also being slashed.
Dale Roberts, deputy leader and portfolio holder for parking on Woking Borough Council, said: 'We remain committed to accessibility in the borough, ensuring our fees and charges are fair, equitable and socially responsible, whilst remaining affordable for the council.
'Administering the scheme costs £30,000 a year, yet data suggests over a third of all permit holders don't make use of them.
'To help cover the cost of administering the permit scheme we will be introducing a small charge for new applications and renewals.'
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Number of council-owned disabled parking spaces dwarfed by blue-badge holders
Number of council-owned disabled parking spaces dwarfed by blue-badge holders

Yahoo

time2 days ago

  • Yahoo

Number of council-owned disabled parking spaces dwarfed by blue-badge holders

The number of council-managed blue parking spaces is significantly dwarfed by the number of blue badge holders, new data shows. According to a study from Swindon Borough Council has 69 dedicated blue badge parking bays, but there are 15,641 blue badge holders. This means that for every 227 permit holders, there is one blue badge space in council-managed areas. According to Swindon Borough Council, the report only focuses on dedicated spaces that belong the the council, but misses the others available in the town. They said: 'To suggest there are only 69 dedicated blue badge parking bays in Swindon is not the case as it ignores all the spaces in supermarkets, private car parks and out of town shopping centres. Disruption after unexpected road closure surprises residents and council 'Waterfalls' spotted on iconic town centre landmark 'left to rot' Five guilty of GBH after 'excessive' defence against knifeman in brawl 'It is also worth noting that, in Swindon, blue badge holders can park in any one of the 876 spaces in our surface level car parks that are not allocated for blue badge parking for as long as they want - for free. 'Holders can also park in a resident bay with their badge on display, with no time restriction, as well as limited waiting bays. And, providing their badge and clock is displayed, blue badge holders can park on double yellow lines for three hours.' According to the same report, there are "3.2 million blue badge permit holders in the UK, in comparison with 63,000 local authority blue badge parking bays". It also seems that the demand for accessible parking is increasing, with there being a 31% increase between 2022 and 2024 for new applications. During the 2022-2024 period, there were nearly 250,000 applications rejected. In England, there are 43,604 parking bays for blue badge holders but 2,635,428 permit holders. Rhydian Jones, motoring expert at car insurance, said: "Blue badge parking spaces are essential for millions of drivers across the UK—but our latest research shows how easily that system struggles. "This is especially highlighted when there isn't enough availability, and other drivers take advantage of the spaces. 'Shockingly, for every one blue badge parking bay in the UK, there are 52 permit holders who need access to it. "If you're using a blue badge space without needing one, even for just a few minutes, you could be stopping someone from being able to work, shop, or attend a medical appointment. "It's clear that more needs to be done—both to increase the number of accessible bays and to prevent misuse. "And if you're caught using a blue badge space without a permit, you could receive a Penalty Charge Notice (PCN) costing between £70 and £100."

Bolton man's plea to council after they 'unfairly fine' him and his disabled wife
Bolton man's plea to council after they 'unfairly fine' him and his disabled wife

Yahoo

time27-05-2025

  • Yahoo

Bolton man's plea to council after they 'unfairly fine' him and his disabled wife

A Bolton man says he's been fined unfairly after parking in a disabled spot while on a seaside day out. James Abercrombie, 48, was in Lytham St Annes with his wife Rachel,46, who has fibromyalgia and uses a wheelchair, for a visit to a food festival. Mr Abercrombie, who lives in Deane, says that when the couple, who have a blue badge on their car, arrived at the resort's council-operated St Pauls Avenue car park, he pulled into a disabled bay, meaning that, according to the council's rule he did not have to pay for a ticket. To his surprise, though, a few days after he returned home from their day trip, he received a parking ticket and was ordered to pay £25, with a letter claiming that he was parked in a non-disabled bay. Read more: Read more: Private car park rule change to reduce fines for UK drivers Read more: 8,000 parking fines issued at Bolton Market car park (Image: Supplied) Mr Abercrombie says the pictures attached to the letter show his Skoda is parked in a disabled bay with hatched markings visible to the side of the car. A picture of Mr Abercrombie's Skoda parked up on the day he visited (Image: Supplied) "Either Fylde Council are blind and can't see I'm parked in a disabled bay, or they have just thought they'll have a stab at taking my money," the 48-year-old said. The couple have been fined an initial £25 for the ticket, which Mr Abercrombie hasn't paid and is disputing, but this will rise to £50 if not paid by May 28. St Pauls Avenue Car Park (Credit: Google Maps)He added: "We'd just come to Lytham for a food festival, and this has happened. "My wife has suffered with cancer and has fibromyalgia, so I push her around on a wheelchair, we just wanted to meet some friends and have a coffee. "You'd think Fylde would want to welcome disabled people for a more diverse audience, but clearly not. Mr Abercrombe says he parked in the middle spot marked with a wheelchair (Image: Supplied) "I could have parked on the double yellows, as we have the right to with a disabled badge, but that would inconvenience other drivers." Mr Abercrombie added: "If we have parked in a non-disabled bay, then it certainly wasn't clearly marked, and if so, why are there only two disabled bays if that's the case?" Fylde Council has been contacted, but has chosen not to comment. Their website states: "If you park in a designated disabled bay [with a blue badge] you can park free of charge for up to 3 hours." The Bolton man says that they were not parked for longer than three hours, and a letter from Fylde Council suggests they believe he parked in a non-disabled bay.

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Yahoo

time23-05-2025

  • Yahoo

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity Opinion follows FDA approval and MHRA conditional marketing authorisation European Commission (EC) decision on conditional marketing authorization application (MAA) expected within approximately two months LONDON, May 23, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended European Commission (EC) approval of obecabtagene autoleucel (obe-cel) for the treatment of adult patients, 26+, with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). 'This positive CHMP opinion is a welcome advancement for physicians and patients in Europe, faced with treating r/r adult B-ALL patients with a poor prognosis,' said Dr. Claire Roddie, MD, PhD, FRCPath, Lead Investigator of the FELIX study and Associate Professor of Haematology at the University College London (UCL) Cancer Institute. 'Obe-cel's combination of favorable tolerability and potential long-term outcomes could offer an important new treatment option for patients in the EU.' The CHMP recommendation was based on the results of the FELIX study, an open-label, multi centre, single arm study in adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia. The results were published in the New England Journal of Medicine in November 20241. In the pivotal cohort of patients, (cohort IIA (n=94)), the Complete Response/Complete Response with Incomplete Haematological Recovery (CR/CRi) for patients who received at least one infusion of obecabtagene autoleucel was 76.6%. Median response duration for all infused patients was 21.2 months. Median event-free survival (EFS) was 11.9 months and the estimated 6- and 12-month event-free survival rates were 65.4% and 49.5%, respectively. The most common non-laboratory Grade 3 or higher adverse reactions were infections-pathogen unspecified (32%), febrile neutropenia (24%) and bacterial infectious disorders (11%). Cytokine release syndrome developed in 87 of the 127 patients (68.5%), with events of grade 3 or higher in three patients (2.4%). Immune effector cell-associated neurotoxicity syndrome developed in 29 of the 127 patients (22.8%), with grade 3 or higher occurring in nine patients (7%). 'This positive opinion from the CHMP highlights the significant unmet need and importance of effective treatment options for adult r/r B-ALL,' said Dr. Christian Itin, Chief Executive Officer of Autolus. 'With FDA approval received in November 2024 and an MHRA conditional marketing authorization received in April 2025, we are on our way to bringing this therapy to patients in need globally.' Obe-cel is an autologous CD19 CAR T cell therapy with a proprietary CD19 CAR, invented by a team led by Dr. Martin Pule, at University College London, along with collaborators at Great Ormond Street Hospital and University College London Hospital. The CAR is designed to have a fast 'off-rate' which mimics physiological T-cell receptor interactions2. ALL is an aggressive type of blood cancer that can also involve the lymph nodes, spleen, liver, central nervous system and other organs. In Europe, there are approximately 6,0002 new cases of ALL diagnosed every year. In frontline treatment for adult B-ALL, up to 50% of patients will ultimately relapse3. Survival rates remain very poor in adult patients with r/r ALL, with median overall survival of eight months with conventional treatments4, and the standard-of-care treatment can trigger severe toxicities5. The positive CHMP opinion is a scientific recommendation for marketing authorization, serving as a basis for the EC's final decision on Autolus' MAA for obe-cel for adult r/r B-ALL patients. The EC is expected to make a decision following CHMP recommendation, and the decision will apply to all 27 European Union Member States, Iceland, Norway and Liechtenstein. Obe-cel is currently approved by the U.S. Food and Drug Administration (FDA) (Nov 8, 2024), and authorized by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) (April 25, 2025). References Roddie C, et al "Obecabtagene autoleucel in B-cell acute lymphoblastic leukemia" N Engl J Med 2024; DOI: 10.1056/NEJMoa2406526 Cancer Research UK - Aureli A, Marziani B, Venditti A, Sconocchia T, Sconocchia G. Acute lymphoblastic leukemia immunotherapy treatment: now, next, and beyond. Cancers (Basel). 2023;15:3346. Dhakal P, Kaur J, Gundabolu K, Bhatt VR. Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents? Leuk Lymphoma. 2020;61:7-17. About Autolus Therapeutics plcAutolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved and MHRA licensed product, obe-cel, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit obe-cel FELIX clinical trialAutolus' Phase 1b/2 clinical trial of obe-cel enrolled adult patients with r/r B-precursor ALL. The trial had a Phase 1b component prior to proceeding to the single arm, Phase 2 clinical trial. The primary endpoint in the pivotal cohort was overall response rate, and the secondary endpoints included duration of response, MRD negative complete remission rate and safety. The trial enrolled over 100 patients across 30 of the leading academic and non-academic centers in the United States, United Kingdom and Europe. [NCT04404660]. Forward Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These risks and uncertainties include, but are not limited to the impact of worsening macroeconomic conditions on Autolus' business, financial position, strategy and anticipated milestones, including Autolus' ability to conduct ongoing and planned clinical trials; Autolus' ability to obtain a clinical supply of current or future product candidates or commercial supply of obe-cel or any future approved products; Autolus' ability to obtain and maintain regulatory approval of its product candidates, including obe-cel and potential expansions into additional indications; Autolus' ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch, market and sell obe-cel and any future approved products; Autolus' ability to obtain marketing approval for obe-cel in additional geographies in the future; the delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise; Autolus' ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates, including obe-cel and potential expansions into additional indications; Autolus' ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch, market and sell obe-cel and any future approved products; Autolus' ability to obtain marketing approval for obe-cel in additional geographies in the future; the delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise; Autolus' ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; competition with respect to market opportunities; and possible safety and efficacy concerns. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus' actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Autolus' Annual Report on Form 10-K filed with the Securities and Exchange Commission, or the SEC, on March 20, 2025 as well as discussions of potential risks, uncertainties, and other important factors in Autolus' subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing Autolus' views as of any date subsequent to the date of this press release. Contact: Amanda Cray +1 617-967-0207 Olivia Manser +44 (0) 7780 471 568 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store